Your Cart ( 1 Item )

• Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial
  August 2018 | Volume 17 | Issue 8 | Original Article | 873 | Copyright © August 2018
  Ellen Frankel MD,^a Michael Song MD,^b Shu Li PhD,^b Jingzhi Jiang MS,^b Robin L. Thurmond PhD,^c Bruce Randazzo MD PhD^c,d
  You will have 48 hours to download the full-text PDF

  Price

  24.95

  Term

  48 Hrs